Could a painless microneedle pad ease Raynaud's in scleroderma?

NCT ID NCT07759557

Not yet recruiting Disease control Sponsor: Khon Kaen University Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This Phase 3 trial is testing whether a microneedle pad delivering botulinum toxin A can improve symptoms of Raynaud's phenomenon and digital ulcers in people with systemic sclerosis. The study compares the microneedle treatment to a placebo, measuring changes in finger temperature and pain scores. The goal is to see if this less invasive method can provide relief without the pain and risks of traditional injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Botulinum toxin A delivered via a microneedle pad
What this could lead to: If effective, this could offer a less painful, non-invasive treatment option for Raynaud's phenomenon and digital ulcers in scleroderma, improving hand function and quality of life.
What could go wrong: The trial is still in Phase 3 with a relatively small number of participants, and results may not confirm the treatment's benefit. There is also a risk of side effects or the microneedle delivery not being as effective as standard injections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RAYNAUD DISEASE SECONDARY TO SCLERODERMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Raynaud disease systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RAYNAUD DISEASE SECONDARY TO SCLERODERMA SYSTEMIC SCLEROSIS (SSC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.